Plus Therapeutics Inc (PSTV) USD0.001

Sell:$0.78Buy:$0.80$0.05 (6.50%)

Prices delayed by at least 15 minutes
Sell:$0.78
Buy:$0.80
Change:$0.05 (6.50%)
Prices delayed by at least 15 minutes
Sell:$0.78
Buy:$0.80
Change:$0.05 (6.50%)
Prices delayed by at least 15 minutes

Company Information

About this company

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Key people

Marc H. Hedrick
President, Chief Executive Officer, Director
Andrew Sims
Chief Financial Officer
Pius Maliakal
Vice President - Clinical Operations
Michael Stanley Rosol
Chief Development Officer
Richard J. Hawkins
Independent Chairman of the Board
Howard Clowes
Independent Director
Robert P. Lenk
Independent Director
Greg B. Petersen
Independent Director
Annigje van Es-Johansson
Independent Director
Click to see more

Key facts

  • EPIC
    PSTV
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US72941H5090
  • Market cap
    $16.72m
  • Employees
    21
  • Shares in issue
    17.26m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.